Nallengare Pharmaceuticlas Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 03-01-2025
- Paid Up Capital ₹ 0.10 M
as on 03-01-2025
- Company Age 41 Year, 5 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 0.87 M
as on 03-01-2025
- Revenue 0.58%
(FY 2017)
- Profit 26.63%
(FY 2017)
- Ebitda -2.54%
(FY 2017)
- Net Worth -28.83%
(FY 2017)
- Total Assets 0.84%
(FY 2017)
About Nallengare Pharmaceuticlas
The Company is engaged in the Chemicals Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹0.87 M.
Milly Varghese and Paul Varghese serve as directors at the Company.
- CIN/LLPIN
U24231KL1983PTC003760
- Company No.
003760
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
21 Jul 1983
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ernakulam
Industry
Company Details
- Location
Thrissur, Kerala, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Nallengare Pharmaceuticlas?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Paul Varghese  | Managing Director | 28-Sep-2010 | Current |
Board Members(1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Milly Varghese | Director | 21-Jul-1983 | Current |
Financial Performance of Nallengare Pharmaceuticlas.
Nallengare Pharmaceuticlas Pvt Ltd, for the financial year ended 2017, experienced modest growth in revenue, with a 0.58% increase. The company also saw a substantial improvement in profitability, with a 26.63% increase in profit. The company's net worth observed a substantial decline by a decrease of 28.83%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Nallengare Pharmaceuticlas?
In 2017, Nallengare Pharmaceuticlas had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Sampanna Kuries (P) Ltd Creation Date: 01 Mar 2001 | ₹0.46 M | Open |
Gampanra Furies (I) Ltd Creation Date: 12 Jul 1988 | ₹0.18 M | Open |
Federal Bank Ltd Creation Date: 18 Dec 1986 | ₹0.02 M | Open |
How Many Employees Work at Nallengare Pharmaceuticlas?
Unlock and access historical data on people associated with Nallengare Pharmaceuticlas, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Nallengare Pharmaceuticlas, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Nallengare Pharmaceuticlas's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
